Article
Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas.
Science advances - 24 Jun 2022
Tiek Deanna M, Erdogdu Beril, Razaghi Roham, Jin Lu, Sadowski Norah, Alamillo-Ferrer Carla, Hogg J Robert, Haddad Bassem R, Drewry David H, Wells Carrow I, Pickett Julie E, Song Xiao, Goenka Anshika, Hu Bo, Goldlust Samuel A, Zuercher William J, Pertea Mihaela, Timp Winston, Cheng Shi-Yuan, Riggins Rebecca B
Abstract excerpt
Temozolomide (TMZ) is a chemotherapeutic agent that has been the first-line standard of care for the aggressive brain cancer glioblastoma (GBM) since 2005. Although initially beneficial, TMZ resistance is universal and second-line interventions are an unmet clinical need. Here, we took advantage of the known mechanism of action of TMZ to target guanines (G) and investigated G-rich G-quadruplex (G4) and splice...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.